ObsEva (NASDAQ:OBSV) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSVFree Report) in a research note released on Monday morning. The firm issued a hold rating on the stock.

ObsEva Price Performance

The firm has a market cap of $156,000.00, a price-to-earnings ratio of 0.00 and a beta of 0.68. The stock has a 50-day moving average of $0.01 and a two-hundred day moving average of $0.04. ObsEva has a 12-month low of $0.08 and a 12-month high of $2.14.

ObsEva Company Profile

(Get Free Report)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Featured Stories

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.